EGFR and neoplasm: As GB is the most common tumor type for which this technology is in widespread use at the current time, our finding that the combination of NF1 mutation, EGFR wild type, and PIK3CA wild type, formulated as a MSS, may be predictive of heightened response to TTFields warrants further investigation, including inclusion as a correlative biomarker in large-scale prospective clinical trials that will be even more robust in the era of more widespread use of TTFields and also comprehensive genomic profiling.